医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Prestige BioPharma Announces Grand Opening of Global-Scale Vaccine Center in South Korea

2021年12月01日 PM01:05
このエントリーをはてなブックマークに追加


 

SINGAPORE

Prestige BioPharma Limited (PBP, 950210: KRX), a Singapore-based biopharmaceutical with operations in USA and South Korea, is pleased to announce the grand opening of its global-scale Vaccine Center in Osong, South Korea.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006182/en/

Prestige Biopharma Vaccine Center (Photo: Business Wire)

Prestige Biopharma Vaccine Center (Photo: Business Wire)

The opening ceremony was held on December 01, 2021 at the Vaccine Center in Osong Campus. The ceremony was attended by many distinguished guests including Minister for Government Policy Coordination Mr. Yun-cheol Koo, Deputy Governor Mr. Il-hong Seong of Chungbuk Province, Mayor of Cheongju City Mr. Beom-deok Han, Representatives from Octava Fund Limited Mr. Joseph Tey and Mr. Sze Khai Pang.

PBP commenced construction of its Vaccine Center April this year and completed the global-scale manufacturing facility with a total area of 10,342.88 m2 and a total capacity of 104,000 litres (52 units of 2,000 liter bioreactors) in only eight months by employing Prestige Biologics (334970: KOSDAQ)’ proprietary engineering technology, ALITA Smart BioFactoryTM. With the ALITA system which provides combined advantages of Stainless Steel & Single-Use system, different types of vaccines can be produced in versatile custom manufacturing suites. The Vaccine Center’s Single-Use bioreactors also enhance operational efficiency and productivity while minimizing the risk of cross contamination.

PBP is currently focusing on two COVID19 vaccine projects to produce Sputink V and Sputink Light vaccines. PBP’s global-scale Vaccine Center is capable of producing around 2.6 billion doses of the first dose of Sputnik V vaccine (Ad26 adenovirus vector) per year.

The center will soon be prepared to produce other types of vaccines including mRNA vaccines to actively respond to the growing demands of COVID19 vaccines.

The company ultimately aims to develop its own vaccine products to combat potential future pandemics and PBP Vaccine Center will be the basecamp for this journey.

PBP’s CEO, Dr Lisa S. Park commented, “We are very pleased to complete the Prestige Biopharma Vaccine Center as planned this year with our Group’s unique and unmatched engineering technology, ALITA Smart BioFactory” and “this Vaccine Center will be playing a significant role in our fight against Covid-19 and possible future pandemics”.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006182/en/

CONTACT

Media enquiries:

Global Communication Team

Prestige BioPharma Ltd.

www.prestigebiopharma.com

Yujin Suh

Tel: +65-6924-6535

info@pbpsg.com

yujin.suh@prestigebio.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Saama Appoints Neelesh Sali to Head, Europe & APAC and Managing Director, India
  • Topcon Introduces NW500 Non-Mydriatic Retinal Camera
  • NewAmsterdam Pharma Announces Initiation of Phase 2 Dose-Finding Study Evaluating Obicetrapib in Japanese Patients
  • デンタル・モニタリングが日本に進出
  • Mitsui Chemicals Group to Exhibit at K2022 Trade Fair in Düsseldorf, Germany